Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression
Part of paid clinical trials in Encino, California.
- Sponsor
- Forest Laboratories
- Study ID
- NCT00852202
- Phase
- PHASE2
- Status
- Completed
Conditions
- Bipolar Depression
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- cariprazine — DRUGDrug: cariprazine (0.25 - 0.75 mg/day)
- cariprazine — DRUGDrug: cariprazine (1.5 - 3.0 mg/day)
- placebo — DRUGplacebo capsules, oral administration, once daily dosing
Study Details
The purpose of this study is to evaluate the efficacy, safety, and tolerability of cariprazine in the treatment of outpatients with bipolar depression.
Key Dates
- Start date
- Jun 30, 2009
- Status verified
- Aug 2018
- Primary completion
- Jun 15, 2010
- Completion
- Jun 15, 2010
Study Design
- Enrollment
- 234 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 10.25 - 0.75 mg/day cariprazine capsules, oral administration, once daily dosing.
- Experimental: 21.5 - 3.0 mg/day cariprazine capsules, oral administration, once daily dosing.
- Placebo Comparator: 3Matching placebo capsules, oral administration, once daily dosing.
Primary Outcome Measure
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: Baseline to Week 8 ]
Locations (26)
Find similar trials in Encino, CA
Related Studies
- Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric PatientsPHASE3 · Recruiting · Intra-Cellular Therapies, Inc. · Dothan, Alabama
- Deep Brain Stimulation of Treatment-Resistant Bipolar DepressionRecruiting · Wayne Goodman MD · Boston, Massachusetts
- A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)PHASE3 · Recruiting · Xenon Pharmaceuticals Inc. · Tucson, Arizona
- An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)PHASE3 · Enrolling By Invitation · Xenon Pharmaceuticals Inc. · Little Rock, Arkansas